Abemaciclib Patent Expiration
Abemaciclib is Used for treating HR-positive, HER2-negative advanced or metastatic breast cancer in various settings. It was first introduced by Eli Lilly And Co
Abemaciclib Patents
Given below is the list of patents protecting Abemaciclib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Verzenio | US7855211 | Protein kinase inhibitors | Sep 28, 2031 | Eli Lilly And Co |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Abemaciclib's patents.
Latest Legal Activities on Abemaciclib's Patents
Given below is the list recent legal activities going on the following patents of Abemaciclib.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Notice of Final Determination -Eligible | 15 Dec, 2023 | US7855211 |
| FDA Final Eligibility Letter Critical | 14 Nov, 2023 | US7855211 |
| transaction for FDA Determination of Regulatory Review Period | 01 Mar, 2023 | US7855211 |
| transaction for FDA Determination of Regulatory Review Period | 18 Jan, 2023 | US7855211 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 19 May, 2022 | US7855211 |
| Second letter to regulating agency to determine regulatory review period | 26 Mar, 2021 | US7855211 |
| Electronic Review Critical | 26 Jun, 2020 | US7855211 |
| Email Notification Critical | 24 Jun, 2020 | US7855211 |
| Mail Certificate of Correction Memo | 23 Jun, 2020 | US7855211 |
| Post Issue Communication - Certificate of Correction | 19 Jun, 2020 | US7855211 |
Abemaciclib's Family Patents
